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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S132compartment compared to control (femur and tibia; +225% p<0.001 and
+42.9% p<0.04 respectively). No effect on the ungrooved lateral
compartment was seen. The histological analysis of the cartilage corrob-
orated these results. A signiﬁcant increase in the OARSI score for the
experimental medial compartment (+225% p<0.001 and +81,7% p<0.006,
respectively for femur and tibia) was seen. Biochemical analysis showed
a decreased PG content in the medial experimental compartment
compared to control (femur -12.09% p¼0.038 and tibia -7.32% p¼0.031).
There was a slight increase in synovial inﬂammation in the experimental
joint (p<0.003). For all previous mentioned analyses, no changes in the
experimental lateral compartment or the control joint were found.
Conclusions: The present study shows clearly that the development of
joint damage is much more dependent on the biomechanical component,
since all detectable damage is in the medial compartment. Joint homeo-
stasis is disturbed, indicated by moderate synovial inﬂammation.
However, this did not lead to generalised OA in this time period.
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Purpose: Since two decades, Autologous Chondrocytes Implantation (ACI)
constitutes a therapeutic alternative in cartilage healing to return back to
a functionally tissue after trauma or age related degeneration. Beyond the
clinical aspect with its encouraging results, themajor goal conditioning the
success of ACI is to obtain a hyaline neo-cartilage with redifferentiated and
phenotypically stabilized chondrocytes. Indeed, the inescapable ampliﬁ-
cation step dedifferentiates chondrocytes, which synthesize a type I non-
functional collagen to the detriment of type II collagen and aggrecan
phenotypic markers. To restart an active metabolism typical of a hyaline
matrix, we developped a clinical suitable process which combine relevant
physicochimic factors for chondrocytes culture such as collagen scaffold,
BMP-2 and IGF-I as chondrogenic factors, physioxic conditions and tran-
sient RNA interference targeting COL1A1 and PSBA (a so-called protein
implied in BMP-2 activity and matrix regulation).
Methods: Dedifferentiated Human Articular Chondrocytes (HAC) from
macroscopically healthy zones but inﬂammatory environment of femoral
heads from patients undergoing joint arthroplasty (age range 52-83) were
cultured in type I collagen sponges, under low oxygen tension, and incu-
bated with BMP-2/IGF-I. siRNAs were used to counteract type I collagen
and to sustain chondrogenic factors activity. An extensive analysis at gene
and protein levels relevant to differentiated, dedifferentiated and hyper-
trophic chondrocyte phenotypes was achieved and used to calculate the
differentiation index corresponding to the ratio of COL2A1 mRNA/COL1A1
mRNA completed by the ratio of type IIB collagen/type IIA collagenmRNAs.
Finally, we have evaluated the behavior of such differentiated chon-
drocytes in vivo, by subcutaneous implantation in the nude mouse model
followed by immunohistochemistry analysis.
Results: Collagen sponges support metabolic activity of viable rediffer-
entiated chondrocytes expressing type II B collagen and aggrecan, without
sign of hypertrophy. The best differentiated phenotype proﬁle was
obtained after 7 days in culture with BMP-2 which enhanced transcription
activity of COL2A1 gene by its speciﬁc enhancer region. The sustained
BMP-2 action by siRNA treatment and COL1A1 down-regulation improved
the differentiation index of chondrocytes, which synthesize a hyaline like-
matrix 28 days after subcutaneous implantation.
Conclusions: HAC phenotype can be restarted and stabilized by this
clinically suitable process with a biodegradable scaffold allowing the
maintenance of chondrocyte characteristics and with a less invasive
surgical method (patent request N10 57683). This study will allow to
develop newmethods for autologous chondrocyte implantation in human.254
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Purpose: Autologous chondrocyte implantation (ACI) is a widely diffused
technique utilized for the treatment of articular cartilage damages. In vitro
expanded chondrocytes for ACI procedure are considered advanced therapy
medicinal products (ATMPs), as deﬁned by the European Regulation.
Consequently, it is mandatory that they have to be manufactured in accor-
dance with the “speciﬁc medicinal rules” named Good Manufacturing
Practices (GMPs) and in dedicated environments built as real “pharmaceu-
tical factories”. This study describes the GMPs development and character-
ization (validation) of chondrocyte-based medicinal products to be used
in ACI.
Methods: Chondrocyte cultures were carried on in a production facility
located in a Public Hospital and including clean rooms of different classi-
ﬁcation up to A in B work places, according to current GMPs (see ﬁgure).
After informed consent, a cartilage biopsy was harvested from a non-
bearing area of the knee of ten patients undergoing ACI. The tissues were
enzymatically digested to isolate chondrocytes. Primary cultures were
expanded in monolayer up to 3-4 passages and cells seeded at deﬁned
density onto matrices derived from collagen I/III (bi-dimensional). Engi-
neered constructs were analyzed for the following parameters: sterility
(microbiological control, Mycoplasma and endotoxins), cell number,
viability and the expression of different phenotypic markers. Microbio-
logical control was performed using an automated system allowing to
reveal the presence of aerobic, anaerobic bacteria and fungi. Highly-
sensitive Real Time Quantitative DNA PCR technology was the method
used for detecting contaminating Mycoplasma. Bacterial endotoxin assays
were performed by quantitative Lymulus Amebocyte Lysate (LAL). Cell
number and viability were evaluated with both an automated cell counter
and the MTT test. Markers typical for hyaline cartilage (collagen II and
aggrecan), ﬁbro-cartilage (collagen I) and bone tissue (osteocalcin) were
evaluated by immuno-histochemical analyses.
Results: Engineered chondrocytes were free of contamination from
aerobic and anaerobic bacteria, fungi, Mycoplasma and endotoxins, viable
(90-98%). The phenotipic analysis revealed that chondrocytes were able to
express the typical hyaline cartilage molecules, collagen II and proteogli-
cans. Collagen I and osteocalcin, markers of ﬁbroblasts a bone, respectively
were not present.
Conclusions: Our results evidentiated the ability to manufacture chon-
drocyte-based medicinal products that are sterile, viable, phenotypically
stable and therefore suitable for ACI application. After this initial validation,
the cultures of 100 patients undergoing ACI were treated in our Cell Factory.Ă
